BioVersys Concludes BV100 Phase 1 Trial in China

BioVersys AG has completed its Phase 1 clinical trial of BV100 in China, marking a significant step in its global development. This trial was crucial for the safety and pharmacokinetic profile of BV100, a potential best-in-class treatment for hospital-acquired and ventilator-associated bacterial pneumonia caused by carbapenem-resistant Acinetobacter baumannii (CRAB).

The completion of this phase will allow Chinese sites to participate in the global Phase 3 RIV-TARGET trial, projected to enroll 300 patients across 100 sites in 15 countries. The trial has achieved its first patient milestone, with top-line data expected in two years.

CRAB poses a severe health risk, particularly in China and Asia, with high resistance rates. BioVersys aims to provide broad access to BV100, addressing a critical need in regions plagued by high infection rates.